Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
New micro-pump technology may offer promising alternative to eye drops for glaucoma patients

New micro-pump technology may offer promising alternative to eye drops for glaucoma patients

Red color channel can help detect diabetic macular edema in racial/ethnic minority patients

Red color channel can help detect diabetic macular edema in racial/ethnic minority patients

Joslin scientists suggest new approach to improve stroke therapy

Joslin scientists suggest new approach to improve stroke therapy

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

New study reveals better treatment options for proliferative diabetic retinopathy

New study reveals better treatment options for proliferative diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Ranibizumab may become reasonable treatment alternative for patients with proliferative diabetic retinopathy

Allergan completes acquisition of AqueSys

Allergan completes acquisition of AqueSys

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

Envisia's ENV515 (travoprost XR) meets primary efficacy endpoint in phase 2a glaucoma trial

ILUVIEN continues to show positive results in Europe

ILUVIEN continues to show positive results in Europe

Alimera Sciences announces results from ongoing study on ILUVIEN

Alimera Sciences announces results from ongoing study on ILUVIEN

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

KalVista raises $33 million in Series B financing to support development of plasma kallikrein inhibitors

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Medicare physician reimbursement data could be confusing to the public

Medicare physician reimbursement data could be confusing to the public

Trained nurses administer AMD treatments as safely and effectively as doctors

Trained nurses administer AMD treatments as safely and effectively as doctors

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Current challenges in tackling macular degeneration: an interview with Mark Ackermann, AMD Alliance International

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces FDA approval of EYLEA (aflibercept) Injection for diabetic retinopathy

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Regeneron announces EU approval of EYLEA (aflibercept) Injection for retinal vascular disease treatment

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME

Johns Hopkins researcher helps discover effectiveness of three drugs for treating patients with DME